US Patent Issued to Ventus Therapeutics U.S. on Sept. 9 for "Pyridazine compounds for inhibiting NLRP3" (Canadian Inventors)

ALEXANDRIA, Va., Sept. 10 -- United States Patent no. 12,410,167, issued on Sept. 9, was assigned to Ventus Therapeutics U.S. Inc. (Waltham, Mass.).

"Pyridazine compounds for inhibiting NLRP3" was invented by Stephane Dorich (Pointe-Claire, Canada), Jason Burch (Pointe-Claire, Canada), Miguel St-Onge (Saint-Lazare, Canada), Amandine Chefson (Montreal), Alexandre Cote (Laval, Canada), Ramsay Beveridge (Pointe-Claire, Canada) and Stephane Ciblat (Montreal).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):"

The patent was filed on Oct. 3, 2023, under Applicat...